Poor Prognosis of Intraoperative Rupture of Mature Cystic Teratoma with Malignant Transformation  by Wen, Kuo-Chang et al.
Taiwanese J Obstet Gynecol • September 2006 • Vol 45 • No 3 253
■ SHORT COMMUNICATION ■
Introduction
Mature cystic teratomas (MCTs) are the most common
ovarian tumors in women of reproductive age. These
tumors are conventionally treated with exploratory
laparotomy [1]. Cystectomy is the most commonly used
procedure and is considered to be a well-accepted pro-
cedure to preserve the fertility of the women, although
a rare malignant transformation (MT) has been reported
[2]. Laparoscopic surgery has gained global popularity
since 1980, and is one of the most important proce-
dural advances in the field of surgery [3,4]. It is effec-
tive in patients with benign ovarian tumors [5–7].
However, MCTs are always challenging for surgeons due
to the potential risk of intraperitoneal rupture causing
spillage of cyst content during laparoscopic surgery or
the less common exploratory laparotomy [3,8,9]. Since
tumor spillage during operation occurs frequently and
is difficult to avoid, some authors have suggested that
surgeons use the so-called controlled spillage method
to deal with patients when this occurs [3]. The fol-
lowing cases demonstrate the possible risk of spillage
after ruptured MCT either during laparoscopy or
laparotomy.
Case Reports
Case 1
A 52-year-old, gravida 5, para 4, woman with no signifi-
cant previous clinical history, was diagnosed with a 5 cm
tuboovarian abscess of the right ovary. A total abdom-
inal hysterectomy and bilateral salpingo-oophorectomy
were performed. During the operation, dense adhesion
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Objective: To present the phenomenon of the postoperative rapid progression of mature cystic teratoma (MCT)
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to the right pelvic wall was found. Intraoperative rupture
of the tumor occurred during dissection. The spillage
material had the usual appearance of MCT, including
yellowish oil, hair and fatty tissue. All of the material
was removed, followed by using a large amount of iso-
tonic sodium chloride solution to clean the abdominal
cavity. One week after the operation, pathology showed
MCT with squamous cell carcinoma (SCC) transfor-
mation (moderate differentiation). The International
Federation of Gynecology and Obstetrics (FIGO) stage
was suggested as IC, although it was not adequately
staged. The patient was then lost to follow-up. After 3
months, the patient visited our hospital due to acute
onset of abdominal pain. Abdominal computed tomog-
raphy demonstrated a 7 cm pelvic complex mass in the
cul-de-sac. Serum levels of SCC antigen and CA-125
were 66.5ng/mL (reference, <1.5ng/mL) and 74 IU/mL
(reference, <35 IU/mL), respectively, before the second-
ary exploratory laparotomy. Exploratory laparotomy
showed a 7 cm tumor mass that had invaded the rec-
tum wall without penetrating into the rectum mucosa.
At the same time, several various sized tumors, ranging
from 0.1 to 0.8 cm, were found scattered over the entire
pelvis, including the vaginal cuff, the right side wall 
of the pelvis and the bladder surface. Optimal debulk-
ing surgery and Hartmann procedure were performed
smoothly. Pathology results showed that the metastases
were similar to the original SCC from the MCT. Initially,
the patient was treated with concurrent chemoradia-
tion (cisplatin 50 mg weekly and radiation 5,040 cGy
for the entire pelvis), followed by additional four-course
adjuvant chemotherapy with a bleomycin, etoposide and
cisplatin (BEP) regimen. The patient was free of disease
6 months after completing therapy.
Case 2
A 32-year-old woman with no past systemic disease
was diagnosed with a 7 cm MCT of the right ovary.
The patient underwent laparoscopic cystectomy, but
tumor spillage occurred during dissection. The tumor
was excised completely and the specimen put into 
an endobag and removed through the umbilical port
wound. A large amount of isotonic sodium chloride
solution was used to clean the abdominal cavity, and
the patient was discharged the next day in a stable
condition. Pathology results showed MCT with SCC
transformation 1 week after the initial operation. FIGO
stage was suggested as IC, although it was not ade-
quately staged. The patient was immediately referred
to our hospital for further management. Serum levels
of SCC antigen and CA-125 were not detected due 
to unknown reasons before the secondary exploratory
laparotomy. Restaging surgery was performed; multiple
metastases of tumors ranging from 0.3 to 0.8 cm cov-
ering the whole pelvic cavity and the omentum were
found. A 2 cm tumor, the largest, had invaded the
muscular layer of the rectum. Optimal debulking sur-
gery, including total hysterectomy, bilateral salpingo-
oophorectomy, appendectomy, infracolic omentectomy,
multiple biopsies and lower rectal resection with end-
to-end anastomosis, was performed. Pathology showed
these tumors to be metastases of SCC, similar to the
original tumor found in the MCT. Cytology results
were positive for malignant cells. The patient under-
went adjuvant chemotherapy, including a BEP regi-
men, a combination of ifosphamide and cisplatin, and
a combination of paclitaxel and carboplatin, but she
died 19 months after the initial operation.
Discussion
Malignancy was found in association with MCT in only
1–3% of cases [2]. The frequency of MT was related 
to age, with the highest incidence in women in their
postmenopausal years. SCC accounts for 70–88% of all
malignant tumors arising in MCT [8]. Although previ-
ous reports [10] have suggested that elderly patients
often had MCT with MT, there is the possibility that
young women may have MT arising from MCT of the
ovary, as in Case 2 of this report. It seems prudent that
in future, MCT in young women should be differenti-
ated from MCT with MT by preoperative examination
with diagnostic tools, including tumor markers and
magnetic resonance imaging. Mori et al [10] reported
that patients with MT averaged 55 years of age and
had high serum SCC antigen levels, which were signi-
ficantly different from those of patients who had 
MCT of the ovary (< 40 years). In addition, Tseng et al
reported that 16 of 24 (67%) patients with SCC arising
in ovarian MCT had elevated SCC antigen levels and
all patients with recurrent lesions had re-elevated anti-
gen levels in a series monitoring SCC. They suggested
that serum SCC antigen monitoring might be helpful
in the early detection of cancer recurrence [11]. In
contrast, Rim et al remarked that serum SCC alone is
not adequate to rule out MT because only 36.3%
(4/11) of MTs showed elevated serum SCC level in
their cases [12]. Therefore, the clinical usefulness of
tumor markers in patients with MT arising in MCT of
the ovary is unclear [13]. Unfortunately, the two
patients in this report failed to undergo these kinds of
examination before their first surgery and an elevated
serum level of SCC was found in only one patient after
tumor recurrence. Altogether, the values of serum SCC
are unclear. Thus, we suggest that preoperative serum
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SCC check-up and postoperative follow-up be done in
cases of MCT.
Approximately 50% of patients with MCT and MT
present with FIGO stage I, and 35–38% of patients
present with stage III diseases [11,14]. Although there
is still no consensus on specific prognostic indicators
for MCT with MT, the grade, FIGO stage of the tumor,
presence of residual disease and vascular invasion have
been shown to be predictive of survival in retrospective
studies [11]. Among these factors, the most important
prognostic indicator of survival has been reported to
be the intact ovarian capsule with confinement of the
tumor within the ovarian tunica (stage IA) [15]. In fact,
early-stage prognosis is good, ranging from 95% to
100% of FIGO stage I, and from 80% to 100% of FIGO
stage II, respectively [11,14]. Till now, in patients with
FIGO classification of stage I ovarian carcinoma, there
is no convincing evidence that intraoperative tumor
rupture promotes metastasis and worsens prognosis
[16]. Patients with tumor rupture during surgery were
staged as FIGO IC and were given adjuvant therapy.
Although it was uncertain whether intraoperative rup-
ture had the same prognostic significance as ovarian
surface involvement and/or positive pelvic washings
[17], more studies have suggested that intraoperative
rupture has not been found to be a predictor of out-
come in stage I ovarian cancer [16,18–21]. In contrast,
the prognostic effects of rupture of the capsules with
spillage and upstaging of MCT with MT that are pos-
sibly IA to more advanced stages, including IIC or III,
remain controversial [22]. Mayer et al reported that
careless intraoperative rupture of the capsule with
spillage of the teratoma content would result in upstag-
ing and additional morbidity [23], and they strongly
recommend that aggressive adjuvant therapy be con-
sidered. As to stage I germ cell ovarian tumor, previous
studies have addressed the issue of whether an intra-
operative rupture influences the prognosis. Several
researchers have concluded that rupture during surgery
was significant only in univariate analyses [20], but
was not significant in multivariate analysis. Furthermore,
intraoperative rupture of ovarian cancer did not trans-
late into shorter survival [2], nor was it a predictor of
outcome [16,18–21]. It is still uncertain and contro-
versial as to whether or not intraoperative rupture of
stage I ovarian cancer truly causes a worse outcome,
and whether all these patients should receive adjuvant
therapy.
In our two cases, we found that progression of
tumor dissemination occurred after the intraoperative
spillage of MCT with MT, favoring a worse prognosis
in this cell type of ovarian germ cell tumor. Because
there were severe dense adhesions between the tumors
and the surrounding tissues, high staging of the tumors
should be first impressed.
Adjuvant treatment after comprehensive staging and
cytoreductive surgery poses another dilemma for clini-
cians managing patients with SCC arising in MCT [15].
The problem stems mainly from the rarity of this tumor
and the small number of patients that have been repor-
ted in the literature. Optimal tumor debulking has been
reported to be associated with a statistically signifi-
cant improvement in survival [11,14]. Postoperative
treatments reported in the literature included single-
agent or combination chemotherapy, radiation ther-
apy, or a combination of these modalities. Due to its
rarity, a definitive or palliative therapy for SCC arising
from a mature teratoma has not yet been established.
In patients with advanced tumors, radiation therapy
has been delivered alone after surgery [24,25], with
inconsistent results and serious adverse events (e.g.
radiation enteritis) [26]. Therefore, we used concurrent
chemoradiation (cisplatin 50 mg weekly and radiation
at 5,040 cGy for the entire pelvis) initially, followed by
additional four-course adjuvant chemotherapy with a
BEP regimen to manage the first case because the
tumors were limited within the pelvic cavity. In the sec-
ond patient, because of the more advanced metas-
tases to the whole abdominal cavity and considering
the possibility of significant morbidity when adding
whole abdominal radiation, we only used multiagent
chemotherapy for the second patient, but this treat-
ment failed.
Multiagent chemotherapy has been delivered in
advanced tumors, but with poor results [24]. It is note-
worthy that some patients were treated using the BEP
regimen, which is a standard for germ cell tumors, but
it is probably misadapted to squamous cell histology
[15]. Donadio et al suggested that chemotherapy for
MT limited to a single cell type results in major res-
ponses and long-term survival in selected patients.
Local therapy after chemotherapy is an important 
component of treatment to achieve maximum response
[27]. The limited amount of reported experiences sug-
gests that multimodal therapy, including aggressive
tumor debulking followed by cisplatin-based combina-
tion chemotherapy or radiotherapy, is effective in this
malignancy [15].
In conclusion, intraoperative rupture of MCT with
MT results in rapid and widespread tumor dissemina-
tion that might worsen the prognosis of patients. So far,
no standard treatment has been applied in this situation.
We hope that future clinical trials will determine a better
strategy to manage these types of patients.
Taiwanese J Obstet Gynecol • September 2006 • Vol 45 • No 3256
K.C. Wen, et al
Acknowledgments
This work was supported, in part, by grants from Taipei
Veterans General Hospital (V95ED1-013; V95B2-003),
Taipei, Taiwan.
References
1. Wang PH, Lee WL, Juang CM, Tsai WY, Chao HT, Yuan CC.
Excision of mature teratoma using culdotomy, with laparo-
scopy and without laparoscopy: a prospective, randomized
trial. Br J Obstet Gynecol 2001;108:91–4.
2. Climie AR, Health LP. Malignant degeneration of benign
cystic teratomas of the ovary. Cancer 1968;22:824–32.
3. Zanetta G, Ferrari L, Mignini-Renzini M, Vignali M, Fadini
R. Laparoscopic excision of ovarian dermoid cysts with
controlled intraoperative spillage. J Reprod Med 1999;44:
815–20.
4. Wang PH, Yuan CC, Lin G, Ng HT, Chao HT. Risk factors
contributing to early occurrence of port site metastases of
laparoscopic surgery for malignancy. Gynecol Oncol 1999;72:
38–44.
5. Liao TW, Chang MY, Chiang CH, Shiao CS, Hsieh TT, Soong
YK. Assessing ovarian reserve in women after laparoscopic
surgery for ovarian endometriosis. Taiwanese J Obstet Gynecol
2004;43:144–8.
6. Remorgida V, Magnasco A, Pizzorno V, Anseini P. Four-year
experience in laparoscopic dissection of intact ovarian der-
moid cysts. J Am Coll Surg 1998;187:519–21.
7. Wang PH, Lee WL, Yuan CC, Chao HT. A prospective ran-
domized study of port wound and culdotomy in extracting
mature teratoma during laparoscopic surgery. J Am Assoc
Gynecol Laparosc 1999;6:39–42.
8. Lin P, Falcone T, Tulandi T. Excision of ovarian dermoid cyst
by laparoscopy and by laparotomy. Am J Obstet Gynecol 1995;
173:769–71.
9. Wang PH, Yuan CC. Laparoscopic excision of ovarian der-
moid cysts with controlled intraoperative spillage. J Reprod
Med 2000;45:965–6. [Letter]
10. Mori Y, Nishii H, Takabe K, et al. Preoperative diagnosis of
MT arising from mature cystic teratoma of the ovary. Gynecol
Oncol 2003;90:338–41.
11. Tseng C, Chou H, Huang K, et al. Squamous cell carcinoma
arising in mature cystic teratoma of the ovary. Gynecol Oncol
1996;63:364–70.
12. Rim SY, Kim SM, Choi HS. Malignant transformation of
ovarian mature cystic teratoma. Int J Gynecol Cancer 2006;
16:140–4.
13. Kimura T, Inoue M, Mihake A. The use of serum TA-4 mon-
itoring patients with malignant transformation to ovarian
mature cystic teratoma. Cancer 1989;64:480–3.
14. Kikkawa F, Ishikawa H, Tamakoshi K, Nawa A, Suganuma
N, Tomoda Y. Squamous cell carcinoma arising from mature
cystic teratoma of the ovary: a clinicopathologic analysis.
Obstet Gynecol 1997;89:1017–22.
15. Lee YC, Abulafia O, Montalto N, Holcomb K, Matthews R,
Golub RW. Malignant transformation of an ovarian mature
cystic teratoma presenting as a rectal mass. Gynecol Oncol
1999;75:499–503.
16. Vergote I, De Brabanter J, Fyles A, et al. Prognostic impor-
tance of differentiation and cyst rupture in stage I invasive
epithelial ovarian carcinoma. Lancet 2001;357:176–82.
17. Leitao MM Jr, Boyd J, Hummer A, et al. Clinicopathologic
analysis of early-stage sporadic ovarian carcinoma. Am J
Surg Pathol 2004;28:147–59.
18. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Torri V,
Mangioni C. The accuracy of staging: an important prog-
nostic determinator in stage I ovarian carcinoma: a multi-
variate analysis. Ann Oncol 1998;9:1097–101.
19. Sevelda P, Dittrich C, Salzer H. Prognostic value of the rup-
ture of the capsule in stage I epithelial carcinoma. Gynecol
Oncol 1989;35:321–2.
20. Ahmed FY, Wiltshaw E, A’Hern RP, et al. Natural history
and prognosis of untreated stage I epithelial ovarian carci-
noma. J Clin Oncol 1996;14:2968–75.
21. Monga M, Carmichael JA, Shelley WE, Kirk ME, Krepart GV,
Jeffrey JF, Pater JL. Surgery without adjuvant chemotherapy
for early epithelial ovarian carcinoma after comprehensive
surgical staging. Gynecol Oncol 1991;43:195–7.
22. Maiman M, Seltzer V, Boyce J. Laparoscopic excision of ovar-
ian neoplasms subsequently found to be malignant. Obstet
Gynecol 1991;77:563–5.
23. Mayer C, Miller DM, Ehlen TG. Peritoneal implantation of
squamous cell carcinoma following rupture of a dermoid cyst
during laparoscopic removal. Gynecol Oncol 2002;84:180–3.
24. Ribeiro G, Hughesdon P, Wiltshaw E. Squamous carcinoma
arising in dermoid cysts and associated with hypercalcemia:
a clinicopathologic study of six cases. Gynecol Oncol 1988;
29:222–30.
25. Stamp GWH, McConnell EM. Malignancy arising in cystic
ovarian teratomas. A report of 24 cases. Br J Obstet Gynecol
1983;90:671–5.
26. Rose PG, Tak WK, Reale FR. Squamous cell carcinoma arising
in a mature cystic teratoma with metastasis to the paraaor-
tic nodes. Gynecol Oncol 1993;50:131–3.
27. Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy
for teratoma with malignant transformation. J Clin Oncol
2003;21:4285–91.
